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Atrial fibrillation (AF) is the commonest cardiac rhythm abnormality and has a significant
disease burden. Amongst its devastating complications is stroke, the risk of which
increases with age. The stroke risk in an older person with AF is therefore tremendous,
and oral-anticoagulation (OAC) therapy is central to minimizing this risk. The presence
of age-associated factors such as frailty and multi-morbidities add complexity to OAC
prescription decisions in older patients and often, OAC is needlessly withheld from
them despite a lack of evidence to support this practice. Generally, this is driven by
an over-estimation of the bleeding risk. This review article provides an overview of
the concepts and controversies in managing AF in older people, with respect to the
existing evidence and current practice. A literature search was conducted on Pubmed
and Cochrane using keywords, and relevant articles published by the 1st of May 2019
were included. The article will shed light on common misconceptions that appear
to serve as rationale for precluding OAC and focus on clinical considerations that
may aid OAC prescription decisions where appropriate, to optimize AF management
using an integrated, multi-disciplinary care approach. This is crucial for all patients,
particularly older individuals who are most vulnerable to the deleterious consequences
of this condition.
Keywords: atrial fibrillation, older people, elderly, management, oral anti-coagulation, stroke, frailty, cognitive
impairment
INTRODUCTION
Atrial fibrillation (AF) is the commonest cardiac rhythm disturbance affecting the general
population. In 2010, the number of individuals with AF in the European Union over the age of
55 years was estimated to be 8.8 million but this is expected to double to 17.9 million by 2060, with
a further 6–12 million likely to be affected in the United States (US) (1, 2). It is a significant public
health burden estimated to cost the UK National Health Service (NHS) and US healthcare £459
million and up to $26 billion, respectively (3, 4).
Although asymptomatic in the vast majority of patients, AF can manifest as ischaemic strokes,
leading to hospitalisations, and death. Indeed, AF is associated with a 5-fold increase in the stroke
risk (5). Its prevalence in the general population increases steadily with advancing age, from 0.12–
0.16% in people younger than 49 years to 3.7–4.2% in those aged 60–70 years. Beyond the age of 80
years, prevalence can be as high as 10–17% (6).
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As age is an independent risk factor for AF, the global
burden of this condition is expected to increase with the
aging population. However, management and treatment of this
common arrhythmia in older people has proven to be a dilemma
for many, as they are a heterogeneous group of individuals
complicated by the presence of functional, and social factors that
contribute to their vulnerability, in addition to multimorbidity
and polypharmacy; all of which need to be taken into account.
It is also partially attributable to the lack of guidelines specific to
this patient population.
We aim to provide an overview of the concepts and
controversies in managing AF in older individuals, with
respect to current practice, and existing evidence. A literature
search was conducted on Pubmed and Cochrane databases
using the keywords “atrial fibrillation,” “oral anti-coagulation,”
“management,” “older,” “elderly,” “falls” “frailty,” and “cognitive
impairment.” Relevant articles published by the 1st of May 2019
were included. Randomized controlled trials (RCTs), systematic
reviews and meta-analyses are presented as they provide a higher
quality of evidence. Other studies including registry studies
and observational studies are also included, as they make-up a
significant proportion of the evidence base for this population,
given the lack of large-scale RCTs, and provide a more “real-
world” perspective on oral anti-coagulation (OAC) use in older
patients.When selecting relevant papers, the overall study design,
and corresponding results were taken into consideration.
AGING AND ATRIAL FIBRILLATION
The relationship between AF and age has been well-described in
the literature and epidemiological studies have been instrumental
in establishing this link. Indeed, advancing age is the most
prominent risk factor for AF. In the Framingham cohort study
which followed individuals over a 22 year period, the incidence
of AF was noted to increase with advancing age. Age, along
with hypertension, congestive heart failure, diabetes mellitus,
coronary artery disease, and valvular disease were identified as
independent risk factors for the development of AF (7, 8). This
was followed by further studies confirming the link between age
and AF, which is now well-established (9–14).
Age is also an independent risk factor for stroke (15). This
was signified in the landmark Atrial Fibrillation Investigators
(AFI) schema which identified age as a predictor of stroke in
AF patients (16). The Stroke Prevention in AF (SPAF) study also
recognized its pertinence, noting that females over 75 years had
a higher rate of thromboembolic events (17). The age-associated
increase in the risk of stroke is not specific to sex and is observed
both in males and females (18–21). In the Framingham study,
stroke risk increased significantly from 1.5 to 23.5% at 50–59
years, and 80–89 years respectively, and in the latter age group,
AF was the sole cardiovascular condition to exert an independent
effect on stroke incidence (10).
Age is not a static but a dynamic risk factor for AF-related
stroke, and risk increases from 65 years and upwards in Western
populations (22). It is a continuous variable, making it difficult
to establish an arbitrary cut-off for risk stratification purposes.
TABLE 1 | Stroke risk stratification: CHA2DS2-VASc score.
Risk factor Score
Congestive heart failure 1
Hypertension 1
Age ≥75 years 2
Diabetes mellitus 1
Stroke/TIA 2
Vascular disease (prior MI,PAD or aortic plaque) 1
Age 65–74 years 1
Sex category: Female 1
The CHA2DS2-VASc score calculates stroke risk in atrial fibrillation. Score of 0 is “low risk”
may not require anticoagulation. Score of 1 in males and ≥2 in females is “low-moderate”
risk and anti-coagulation may be considered as per ESC guidelines. A score of≥2 and≥3
in males and females respectively, is “moderate-high” risk and anticoagulation is indicated.
Maximum possible score = 9; TIA-transient ischemic attack; MI-myocardial infarction;
PAD-peripheral arterial disease.
Table 1 outlines the current version of the CHA2DS2-VASc risk
stratification tool which is most widely used in clinical practice.
PATHOPHYSIOLOGY OF AF IN OLDER
INDIVIDUALS
The numerous risk factors that increase the propensity for AF can
be grouped into modifiable or non-modifiable risk factors (23).
Modifiable risk factors include body mass index (BMI), diabetes,
obstructive sleep apnoea (OSA) and hypertension whereas the
non-modifiable risk factors include genetics, gender, ethnicity,
and of course, age (24). These increase susceptibility to AF by
inducing structural and histopathological changes.
The onset of AF requires both an initiating trigger and an
anatomical substrate; in this case, a critical mass of abnormal
tissue that can provoke atrial ectopic beats and give rise to
paroxysms of AF. The pulmonary veins (PVs) may be the
main origin for ectopic triggering foci (25, 26). Nevertheless,
the exact pathophysiological mechanisms linking age and AF
are poorly understood. In older patients, the presence of
multiple comorbidities adds to the complexity of establishing
the impact of aging vs. the impact of comorbidities on the
development of AF, in isolation. The aging heart offers an ideal
environment for AF to flourish in the presence of predisposing
“anatomical substrate” abnormalities, due to conditions such
as hypertension, ischaemic heart disease, heart failure, valvular
disease, and dilated/hypertrophic cardiomyopathy (27, 28).
These have been associated with histopathological and atrial
chamber abnormalities which result in myocardial fibrosis and
atrial dilation, thus increasing the risk of AF (29). In addition,
the stretching of the atrial fibers due to atrial enlargement leads
to a shorter refractory period and slower electrical conduction,
further optimizing the conditions for arrhythmogenicity (27).
Over time, repeated episodes of AF lead to further substrate
abnormality through structural and electrophysiological
remodeling, and modify the cell to cell conduction, resulting
in a reduced threshold for AF triggers and conditions which
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sustain AF (30). AF therefore gives rise to additional risk
factors which contribute to its own progression; hence, “AF
begets AF,” explaining how paroxysmal episodes progress into
permanent sustained episodes over a period of time. The longer
the treatment is delayed, the more difficult it is to regain sinus
rhythm (27).
ANTICOAGULATION IN OLDER PEOPLE
Stroke risk is not homogeneous and risk factors have been used
to formulate various stroke (and bleeding) risk stratification
schemes (31). Risk is not a static “one off” process but is dynamic
in nature, and the change in risk profile leads to an increased risk
for outcomes (32, 33).
Both the European Society of Cardiology (ESC) and National
Institute for Health and Care Excellence (NICE) guidelines (UK)
recommend assessment of stroke risk using the CHA2DS2-VASc
score with view to consideringOAC for scores of ≥1 inmales and
≥2 in females (34, 35). OAC with a vitamin K antagonist (VKA)
or the newer non-vitamin K antagonist oral anti-coagulants
(NOACs) must be recommended for those who meet the criteria.
The guidelines are in agreement that OACs are superior to
aspirin and aspirinmonotherapy should not be offered to patients
with AF, solely for stroke prevention. The American College of
Cardiology/American Heart Association/Heart Rhythm Society
(ACC/AHA/HRS) guidelines differ slightly with OAC being
recommended for higher CHA2DS2-VASc scores of ≥2 and ≥3
in men and women, respectively. For scores of 1, management
options include withholding OAC, or treatment either with an
OAC or aspirin (36).
Given that the default is to offer stroke prevention unless
patients are “low risk,” the recommendations have shifted to
initially identify low risk patients first (rather than high risk ones)
who do not need any antithrombotic therapy (37). The next step
is to offer stroke prevention to those with ≥1 additional stroke
risk factors (38).
Perceptions Regarding Oral
Anti-coagulation
As previously established, both age and AF are independent risk
factors for stroke, meaning that the older patient with AF is
particularly vulnerable to developing a stroke (15). The meta-
analysis by Albertsen et al. (39) showed that older patients are
more likely to have a stroke even when on an OAC, despite a 64%
stroke risk reductionwith warfarin (40). Indeed, this suggests that
there is greater benefit to be derived fromOACs by those who are
older. Despite this, OAC underuse remains a pressing issue in the
older patient population (41).
Pugh et al. (42) in a systematic review explored physicians’
attitudes toward OAC for stroke prevention in older people.
Barriers to OAC prescription in order of most cited reasons
included bleeding risk, falls risk, age, and patients’ ability to
comply with the treatment regimen. The study also reported
that even in the absence of any contraindications to warfarin,
physicians were still unlikely to recommend OAC for patients
over 70 compared to those ≤70 years of age. In another
review, limited evidence or perceived uncertainty, the need
for individualized decision making and feelings of delegated
responsibility were identified as key physician concerns which
deterred them from prescribing OAC (43).
These reservations by clinicians are partially justified by the
limited evidence specific to this cohort. Few RCTs specific to
older people have been carried out and even then, older patients
are under-represented in the existing RCTs. In most cases, results
from such studies are extended to these patients and their direct
applicability to the older individual is frequently questioned.
In addition, the CHA2DS2-VASc score which is largely driven
by age is poorly helpful in determining the therapeutic approach
in older individuals. This is particularly true for those over
75 years, for whom OAC therapy is indicated by definition,
regardless of the presence of other factors. In essence, this makes
the tool almost unnecessary in cardio-geriatric practice and
what would be more helpful is a decision-making guide that
incorporates factors such as frailty, and comorbidities such as
dementia which influence treatment decisions in this age group.
This is also true for the bleeding risk scoring systems, most of
which incorporate age, and stroke. Thus, the overlap in these
components of the risk stratification scores result in a parallel
increase in the stroke and bleeding risks that is less helpful and
to a certain extent, these scores almost seem like an oxymoron.
Indeed, risk stratification scores serve as tools to guide
treatment decisions and must not be used as replacements for
existing evidence and/or clinical judgement, i.e., bleeding risk
scores should be used to identify patients who are at a higher risk
of bleeding, to initiate closer monitoring strategies as advocated
by the guidelines (34, 36). Yet, they are often used to justify
withholding OAC therapy from patients who have an equal or
higher risk of stroke (44). In their study, Friberg et al. (45),
demonstrated that the risk of ischaemic stroke without OAC
was higher than the risk of bleeding with OAC, unless the risk
of ischaemic stroke was very low (CHA2DS2-VASc = 0). For
a patient with a CHA2DS2-VASc and HAS-BLED (comprising
of hypertension, renal impairment, liver dysfunction, stroke
history, prior major bleeding, or predisposition to bleeding, labile
INR, age >65 years, medications predisposing to bleeding and
drug/alcohol use) score of 5, the net clinical benefit (NCB) of
OAC was still 3% per year, even with a weight of 1.5 applied
to intra-cranial hemorrhage (ICH) events, to account for their
disastrous consequences.
Nonetheless, decision-making aids that are more specific
to older people, inclusive of age-associated factors, may help
minimize some of the physician concerns and uncertainties
toward prescribing OAC.
Conventional Oral Anticoagulants
In the general population, it is well-established that warfarin
is superior to both mono and dual anti-platelet therapy. In
a systematic review and network meta-analysis, López-López
et al. (46) demonstrated that aspirin <150mg once daily [OR
1.88 (1.40 to 2.51)] and aspirin ≥150mg once daily [OR
1.61 (1.25 to 2.07)] were both inferior to warfarin (INR 2–
3) for prevention of stroke and systemic embolism in patients
with AF. Major bleeding in patients receiving warfarin was
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TABLE 2 | Secondary analyses studies of the phase III trials of NOACs vs. warfarin.
Study Population Older patients % Intervention Stroke & SE (95% CI) Major bleeding (95% CI)
RE-LY (55) 18,113 <75 years: 59.9
75–79 years: 23.4
80–84 years: 12.7
>85 years: 4.0
Dabigatran 110mg
b.i.d
Dabigatran
150mg b.i.d
<75: HR 0.93 (0.70–1.22),
75–79 HR 1.08 (0.73–1.60), 80–84
HR 0.75 (0.46–1.23), ≥85 HR 0.52
(0.21–1.29)
P interaction = 0.394
<75 HR 0.63 (0.46–0.86), 75–79 HR
0.65 (0.42–1.01), 80–84 HR 0.67
(0.41–1.10), ≥85 HR 0.70 (0.31–1.57)
P interaction = 0.996
<75 HR 0.62 (0.50–0.77),
75–79 HR 0.93 (0.71–1.21),
80–84 HR 1.18 (0.84–1.65), ≥85 HR
1.01 (0.59–1.73)
P interaction = 0.006
<75 HR 0.70 (0.57–0.86), 75–79 HR
1.04 (0.81–1.35), 80-84 HR 1.41
(1.02–1.94), ≥85 HR 1.22 (0.74–2.02)
P interaction = 0.001
ROCKET AF (56) 14,264 >75 years: 43.7 Rivaroxaban 20mg
daily
<75 HR 0.95 (0.76–1.19),
≥75 HR 0.80 (0.63–1.02)
P interaction P = 0.313
<75 HR 0.96 (0.78–1.19)
≥75 HR 1.11 (0.92–1.34)
P interaction P = 0.336
ARISTOTLE (57) 18,201 <65 years: 30.1
65–74 years: 38.7
>75 years: 31.2
Apixaban 5 b.i.d <65 HR1.16 (0.77–1.73),
65–74 HR 0.72 (0.54–0.96),
>75 HR 71 (0.53–0.95).
P interaction = 0.11
<65 HR 0.78 (0.55–1.11), 65–74 HR
0.71 (0.56–0.89),
> 75 0.64 (0.52–0.79),
P interaction = 0.63
ENGAGE AF-TIMI
48 (58)
21,105 <65 years: 26.0
65–74 years: 33.8
>75 years: 40.2
Edoxaban 60mg daily <65 HR 0.94 (0.65–1.37), 65–74 HR
0.89 (0.68–1.16),>75 HR 0.83
(0.66-1.04).
P interaction = 0.84
<65 HR 0.81 (0.58–1.12), 65–74 HR
0.75 (0.60–0.94),>75 HR 0.83
(0.7–0.99).
P interaction = 0.78
RE-LY, Randomized evaluation of long-term anticoagulation; ROCKET-AF, Rivaroxaban for stroke prevention in patients with non-valvular atrial fibrillation; ARISTOTLE, Apixaban for
reduction in stroke and other thromboembolic events in atrial atrial fibrillation; ENGAGE AF-TIMI 48, Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-
Thrombolysis In Myocardial Infarction; b.i.d, twice daily. All studies used dose adjusted Warfarin INR 2.0–3.0. HR, Hazard Ratio; CI, confidence interval; Bold, significant interaction; SE,
systemic embolism.
comparable to patients on anti-platelets. Of the RCTs included
in this meta-analysis only 3 trials [AF-ASA-VKACHINA (47),
BAFTA (48), and WASPO (49)] selectively investigated the older
population, comparing antiplatelet therapy with warfarin. To
date, BAFTA is the largest RCT involving older AF patients.
The multi-center RCT randomized 973 patients into dose-
adjusted warfarin (INR target 2–3) or aspirin 75mg daily
treatment arms. The warfarin group had fewer numbers of
strokes [OR 0.52, 95% CI (0.33–0.80)] and the same number of
major hemorrhages [0.96, 95% CI (0.53–1.75)] compared to the
aspirin group.
In a more recent meta-regression analysis, Bai et al. (50)
identified six studies (47–49, 51–53) that specifically looked
at warfarin vs. aspirin in the older population (defined as
age ≥65 years old). Unsurprisingly, warfarin was superior to
aspirin for the prevention of stroke/thromboembolism [RR
0.44, 95%CI (0.24–0.64)] with no significant increase in major
bleeding (RR 1.20, 95%CI [0.91–1.50]). With advancing age,
the RR for stroke/thromboembolism for warfarin vs. aspirin
was attenuated (r2 = 0.76, P = 0.002) but no significant
reductions were observed in the RR for major bleeding
(r2 = 0.20, P = 0.22).
Newer Oral Anticoagulants
The NOACs, also referred to as direct oral anticoagulants
(DOACs), provide an alternative to warfarin for
thromboprophylaxis. They may be more favorable in the
older person, given that they do not require routine monitoring,
have a wider therapeutic window and have fewer food and drug
interactions unlike warfarin (54).
The efficacy and safety of NOACs have been demonstrated in
large RCTs comparing these drugs (i.e. dabigatran, rivaroxaban,
apixaban and edoxaban) to warfarin (55–58). These are
supported by numerous “real world” studies which have also
demonstrated these findings. (33, 59). However, in these RCTs,
older patients were under-represented with less than half of
the study populations comprising of participants ≥75 years of
age. Subsequent analyses of the data from these trials (Table 2)
demonstrated that NOACs were non-inferior to dose adjusted
warfarin for the prevention of stroke and systemic emboli even
in the older cohorts (60–63). Despite this, an issue consistently
raised by clinicians with respect to these trials is that they are
not truly reflective of real-world practice. Study participants
are not regarded as accurate depictions of real-world patients,
as they represent a minority who are uncomplicated and “fit”
enough to fulfill stringent study criteria. Further, many of the
systematic reviews and meta-analyses comparing warfarin to
NOACs are based on RCT data, with few based on real world
studies and focused on older people (Table 3). Nonetheless,
these results indicate that NOACs are generally preferable
to warfarin for prevention of stroke and systemic emboli in
patients aged ≥75 years, while the rates of major bleeding
are comparable.
Given that every NOAC has its own efficacy and safety
profile, comparing them collectively as a group against warfarin
would not be just, nor would it provide clinicians with an
accurate idea of their benefits and risks with real-world use.
Lin et al. (69), in their systematic review and network meta-
analysis, have shed some light on this. Their study included
both RCTs and non-RCTs to provide a real-world assessment of
the NOACs. They compared dabigatran, rivaroxaban, apixaban,
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TABLE 3 | Meta-analysis of NOACs vs. Warfarin for stroke prevention in older individuals with AF.
References Study design Comparison Stroke/SSE (95%CI) Major hemorrhage (95% CI)
Bai et al. (50) SR + MRA
(RCT = 7, cohort = 7,
national registry = 1
and observational = 1)
NOAC† vs. Warfarin ≥65 years: HR 0.81 (0.73–0.89) ≥65 years: HR 0.87 (0.77–0.97)
Kim et al. (64) SR + MA (RCT = 5) NOAC† vs. Warfarin ≥ 75 years: RR 0.83, (0.69–1.00) equivalent safety*
Ruff et al. (65) MA (RCT = 4) NOAC† vs. Warfarin <75 years RR 0·85 (0·73–0·99)
≥75 years RR 0·78 (0·68–0·88)
<75 years RR 0·79 (0·67–0·94)
≥75 years RR 0·93 (0·74–1·17)
Briceno et al. (66) SR+MA
(RCT = 7)
NOAC† vs. Warfarin ≥75 years: OR 0.77 (0.68–0.87) *
Sardar et al. (67) MA
(RCT = 10)
NOAC‡ vs. conventional
therapy§
≥75 years: OR 0.65 (0.48–0.87) ≥75 years: OR 1.02 (0.73–1.43)
Lega et al. (68) MA
(RCT = 3)
NOAC‡ vs. Warfarin <75 years RR 0.83 (0.71–0.96)
≥75 years: RR 0.77 (0.67–0.89)
<75 years RR 0.73 (0.65–0.81)
≥75 years RR 0.90 (0.82–1.00)
SSE, Stroke or systemic embolism; HR, Hazard Ratio; RR, Relative risk; OR, Odds ratio; SR, Systematic review. MA, meta-analysis; MRA, Meta-regression analysis; RCT, Randomized
controlled trials; *Not reported;
†
NOACs included were dabigatran, rivaroxaban, apixaban, and edoxaban; ‡NOACs included dabigatran, rivaroxaban, and apixaban; §conventional
therapy included Vitamin K antagonists, low-molecular weight heparin, aspirin, and placebo.
and edoxaban individually with warfarin for stroke and systemic
emboli (SSE) and major hemorrhage. In patients aged ≥75
years, dabigatran 150mg and apixaban both significantly reduced
events of SSE (rate ratio 0.74 and 0.69 respectively, 95% CI<1 for
both), whilst other NOACs showed no significant differences to
warfarin. In terms of adverse events, only apixabanwas associated
with a clinically significant reduction in major bleeding in older
people [rate ratio 0.67 (95%CI 0.55–0.82)]; all other NOACswere
similar to warfarin for major bleeding.
BLEEDING RISK
Like the stroke risk, advancing age is also accompanied with
an increased propensity for bleeding and this bleeding risk is
a commonly cited reason for OAC underuse and inappropriate
cessation (70, 71). OAC cessation leads to worse outcomes
amongst older people (72, 73). Indeed, the HAS-BLED scoring
system recognizes age as an independent risk factor for bleeding
in anticoagulated patients and a score of ≥3 classifies individuals
as “high-risk” (Table 4) (74). However, both the NICE and ESC
guidelines recommend using the score to identify and treat
reversible risk factors associated with this increased risk rather
than denying patients of OAC based on the score alone (34, 35).
The risk of major bleeding associated with warfarin has been
explored in a number of reviews; but, the studies included have
variable definitions of major bleeding with some considering only
extra-cranial bleeding events and others including all bleeding
events. Current opinion on the major bleeding risk is mixed as
some studies report higher risks with warfarin (75–79), whilst
others do not report any significant differences (50, 80, 81).
Nonetheless, all RCTs for NOACs have consistently reported
a significantly lower risk of ICH compared to warfarin (55–58).
ICH is one of the most feared complications of OAC, particularly
in older individuals and can often be a terminal event in this age
group. Chao et al. (82), in a nationwide cohort study looked at
the use of OAC in very old patients (≥90 years) with AF. They
noted that in these nonagenarian, warfarin use was not associated
TABLE 4 | Bleeding risk with oral anti-coagulation: HAS-BLED score.
Characteristic Score
Uncontrolled Hypertension 1
Abnormal renal and/or liver function 1-2
Stroke history 1
Bleeding 1
Labile INR 1
Age >65 years 1
Drugs and/or alcohol 1-2
Maximum 9 points. Hypertension defined as systolic >160mm Hg. Renal disease is
dialysis, transplant, creatinine >200 µmol/L. Liver disease is cirrhosis or biochemical
evidence of liver derangement (bilirubin >2x normal with AST/ALT/AP >3x normal).
Bleeding is either prior major bleeding or predisposition to bleeding (e.g., bleeding
diathesis, anemia). Labile INR [international normalized ratios] is unstable/high INR or a
time in therapeutic range (TTR) of <60%. Drugs refer to medications predisposing to
bleeding (e.g., aspirin, clopidogrel, and NSAIDs]. Alcohol is ≥8 drinks/week.
with an increased risk of ICH that was of statistical significance,
compared to patients who were not on antithrombotic therapy
[HR 1.22 (95% CI 0.68–2.18), p = 0.512]. The study also had a
second cohort where comparisons were made between warfarin
and NOACs. Although stroke risks were similar, the ICH risk
was markedly lower with NOACs, indicating that the NCB is
higher with these drugs. A similar study by Alnsasra et al. (83)
demonstrated a positive NCB favoring OAC therapy in patients
over the age of 75 years, with the greatest NCB observed in
the group aged 75–84 years, those treated with higher doses of
DOACs or with a time in therapeutic range (TTR) of ≥60%
(if warfarin treated), highlighting the importance of optimal
dosing (84).
NOACs in general, have been shown to have satisfactory
safety profiles compared to warfarin in those who are older, with
some even demonstrating superiority over the VKA in certain
domains (Table 3). Despite this, the lack of a uniform and well-
defined guidance for clinicians on the selection of an appropriate
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OAC/NOAC has resulted in a largely varied practice across the
globe, not necessarily dependent on the safety profiles of the
drugs. In the initial stages, dabigatran, a drug with a relatively
higher risk of overdose and GI bleeding, due to the longer half-
life, and predominant renal dependence for clearance, was avidly
prescribed. This may have been because dabigatran was the only
approved NOAC at one point in time that also had a reversal
agent. However, recent evidence has demonstrated declining
prescription rates for dabigatran, particularly in older patients
(85, 86). Increasing awareness, availability of other NOACs and
the development of antidotes for these may be amongst the
contributing reasons.
Sharma et al. (87) reviewed the safety and efficacy of NOACs
in a large systematic review and meta-analysis that included RCT
data on NOACs prescribed for both stroke prevention in AF
as well as secondary prevention of venous thromboembolism.
Compared to VKAs, apixaban, and edoxaban were associated
with significant reductions in major hemorrhage [odds ratio
[OR] range 0.63–0.81, 95% CI <1, p < 0.05 for both] in
the population aged ≥75 years. However, both dabigatran
150mg (OR 1.78, 95% CI 1.35–2.35), and 110mg (OR 1.40,
95% CI 1.04–1.90) increased the risk of GI bleeding in these
patients. Regardless, dabigatran 150mg (OR 0.43, 95% CI
0.26–0.72), and 110mg (OR 0.36, 95% CI 0.22–0.61) still had
significantly lower risks of ICH when compared to VKAs. These
observations have been replicated in a meta-analysis of real-
world studies by Romanelli et al. (88) where both dabigatran
150 and 110mg were associated with a significantly lower
risk of ICH compared to warfarin. However, patients aged
≥75 years had an ∼50% higher chance of gastrointestinal
bleeding compared to younger patients. The findings warrant
caution when prescribing high dose dabigatran for older
individuals, who have multiple concomitant risk factors for
GI bleeding.
The analysis of phase III trial data also showed that
rivaroxaban is non-inferior to warfarin and is not associated
with significant major bleeding (Table 2). However, significantly
higher rates of the combined end point of major bleeding and
clinically relevant non-major bleeding (P interaction = 0.009)
were observed in older patients taking rivaroxaban. This was
thought to be driven primarily by gastrointestinal bleeding.
However, analysis of NCB based on prevention of ischaemic
stroke, life threatening bleeding and all-cause mortality indicated
that the overall benefit of rivaroxaban over warfarin was still
higher in the older cohort (60).
In a sub-analysis of the ARISTOTLE trial, apixaban was
associated with lower rates of major bleeding (HR 0.66, 95% CI
0.48–0.90), and ICH (HR 0.36, 95% CI 0.17–0.77) in patients≥80
years of age, relative to warfarin. In the AVERROES trial which
compared apixaban and aspirin, rates of major bleeding were
similar for ≥75 and ≥85 age groups (89). Further, the ENGAGE
AF-TIMI 48 trial also suggested a greater NCB with edoxaban
with advancing age. The post-hoc analysis demonstrated that
the benefits were maintained even in the extremes of age (≥80
and ≥85 years) (62). Again, this was primarily thought to be
due to the reduction in major bleeding and ICH associated
with edoxaban.
Understandably the decision to initiate OAC in older patients
and the choice of anticoagulant, can pose a dilemma for clinicians
but often, this can be driven by patients’ risk factor profiles
and preferences. A study by Devereaux et al. (90) showed that
compared to physicians, patients placed more value on avoiding
strokes rather than avoiding bleeding. The authors strongly
recommended giving importance to what patients considered
significant during the decision-making process. Some may favor
stroke prevention and accept the bleeding risk whilst others, may
choose not to take a medication that may increase their risk
of bleeding.
The lack of direct comparisons between the NOACs and the
heterogeneity in patient populations between the phase III trials
add to the challenge of deriving clear guidelines for NOAC use in
older patients. Hence, the choice of NOAC should be based on a
comprehensive review of comorbidities such as renal dysfunction
and other variables such as cognitive decline, nutrition status,
and polypharmacy.
FRAILTY
Frailty is described as a clinically recognizable state of increased
vulnerability due to an age-associated decline in reserve and
function across multiple physiological systems, compromising
an individual’s ability to cope with daily activities or acute
stressors (91). The growing understanding of its association with
the risk of adverse outcomes such as falls, worsening disability,
hospitalisations andmortality has led to a significant focus on this
syndrome (92). Frailty is thought to be reflective of an individual’s
biological age; a more accurate predictor for the occurrence of
such adversities compared to chronological age. That said, it
is more prevalent in those who are >65 years, and females in
particular (93, 94).
While a quarter to three quarters of people over the age of
85 years is thought to be frail, up to three quarters may also
not be frail, suggesting that there are significant variations in the
way frailty develops, is assessed, and classed (95). Data on the
prevalence of frailty in patients with AF is limited in the literature,
highlighting a lack of research in this field. A recent systematic
review of 11 studies by Villani et al. (93) focusing on this very
subject, identified a frailty prevalence ranging from 4.4 to 75.4%.
Age was regarded as the principle factor for the large variation,
given the low prevalence of 4.4% reported in the study by Ng
et al. (96), where the mean age of the participants was lower at
66.7 ± 7.8 years. However, it is worth noting that the majority of
the included studies were based on hospitalized in-patients whose
general health is likely to have been poorer. In another meta-
analysis by Wilkinson et al. (97), frailty prevalence in AF patients
varied from about 6% in a registry of outpatients to about 100%
in a nursing home population. This suggests that the numbers
quoted in studies are largely dependent on the study setting
and likely overestimated as most are hospital based. Further,
the criteria for assessing frailty differed between the studies,
preventing direct comparisons. Hence, the true prevalence of
frailty in the general AF population is yet to be determined and
longitudinal studies where frailty assessment is based on more
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homogeneous criteria are needed (93). Like many factors, frailty
status is dynamic and subject to change over time.
There are a variety of tools used in the identification,
assessment and gradation of frailty. Broadly speaking, the
concept of frailty is based on two main models (Table 5); the
phenotype model (Fried’s Criteria) and the cumulative deficits
model [Frailty Risk Index/Frailty Index (FI)]. Subsequent tools
building on these, such as the Rockwood Clinical Frailty Scale,
Edmonton Frail Scale, and the Groningen Frailty Indicator have
since developed (99–101).
The phenotype model, based on physical and functional
indicators, was developed by Fried et al. (102) using data
from the Cardiovascular Health Study (CHS), performed on a
community-dwelling population. The landmark study identified
comorbidity as a risk factor for, and disability as a consequence
of frailty, describing an overlap but distinguishing between
the three. Five pre-defined criteria which include unintentional
weight loss (of more than 10 lbs in the past year), self-reported
exhaustion, weakness (assessed by grip strength), slow walking
speed and low physical activity are assessed and a point is
allocated for each variable if present. A score of 0, 1–2 and
3 represent individuals who are robust, at risk of developing
frailty (pre-frail) and frail, respectively. Although this model
enables assessment of the frailty status in individuals without the
need for a comprehensive clinical assessment, it does not offer
any information about the underlying conditions which may be
contributing to the presence of these variables. Further, the tasks
though simple at first glance, may be challenging to execute in the
presence of certain physical and cognitive limitations, and in the
absence of equipment such as hand-held dynamometers that are
not readily available in the clinical setting.
The cumulative-deficits model in contrast, was developed
from the Canadian Study of Health and Aging (CSHA) and
assumes that frailty is a result of an accumulation of individual
deficits (inclusive of symptoms, signs, abnormal laboratory
values, disease classifications, and disabilities) (103, 104). A
comprehensive geriatric assessment is required and each variable
whether a hearing impairment or a diagnosis of atrial fibrillation
is presumed to have an equal effect on the frailty status and
risk of adverse outcomes. The FI is derived from a mathematical
calculation where the number of individual “deficits” possessed
by an individual is divided by the total number of variables or
deficits measured. For example, if 10 of 20 variables are present,
the FI is 10/20 = 0.5. The number derived may be used as a
continuous variable (i.e. the higher the number, the more likely
an individual is to be frail and the less their physiological reserve
will be, to adapt to stressors and allow accumulation of further
deficits) (103, 105).
The FI is particularly advantageous in the long-term follow-up
of a patient as changes to this number highlight improvements
or worsening of the frailty status. This also emphasizes the
notion that frailty is gradable rather than being present/absent
(105). The FI has also been categorized using pre-defined cut-off
points by Rockwood et al. which have varied in studies. In
one of their studies, classifications were made as follows: ≤
0.03–relatively fit, >0.031–≤ 0.10–less fit, >0.10–≤ 0.21–least
fit, >0.21–≤0.45–frail, and ≥0.45–most frail and in another,
the FI cut-off for frailty was ≥0.25 (98, 106). Although the
original study involved assessment of 92 different parameters,
subsequent research has indicated that this can be reduced to
a more feasible number of about 30, without loss of predictive
value (103). Thus, items included in the FI are not fixed and any
variable (that fulfills specified criteria) can be incorporated.While
this allows flexibility, the lack of a standardized “proforma” and
categorisations that translate into classes of risk pose issues in
clinical practice as well as research.
Despite the unique features between the phenotype and
cumulative deficits models, a significant overlap exists in their
ability to predict future adverse health outcomes such as falls
and death (107). Their applicability and usefulness however,
may depend on the general state of an individual at the time
of evaluation. The correct and combined use of both models
is therefore recommended as they provide complementary
information on the individuals and their risk factor profiles
(105). However, the exhaustive nature of the models limits
their use as quick and convenient bed-side screening tools
that can be used easily by clinicians. Currently, comprehensive
geriatric assessments are considered the “gold-standard” for
frailty assessment (108).
Frailty is extremely relevant to the older AF population
as it is one of the most commonly cited reasons for OAC
under-prescription when in fact, frail patients may stand to
achieve the most benefit from it (109, 110). In a recent systematic
review and meta-analysis, Oqab et al. (111) demonstrated that
frailty significantly reduced the prescription of OAC (OR 0.49,
95% CI 0.32–0.74), with cognitive impairment and malnutrition
amongst the other commonly cited geriatric reasons. One
explanation for this is the association between frailty and falls and
the consequent risk of ICH.
According to a meta-analysis by Cheng et al. (112) frail older
adults are at a higher risk of having recurrent falls compared
to the pre-frail and robust older adults groups. Whilst this may
be an irrevocable fact, it is important to consider the individual
factors contributing to the individual’s frailty status and falls
risk. Frailty does not equate to having falls and often, the risk
of falls can correspond to potentially reversible factors and
be minimized by addressing these. This includes provision of
visual and hearing aids for those with sensory impairments,
performance of mobility assessments on at-risk patients such
as those with gait impediments, provision of mobility aids and
balance-improving exercises for patients who require them and
adjustments to the general area of living where needed (113).
To further evaluate the OAC-associated bleeding risk in AF
patients who were at risk of developing falls, Man-Son-Hing
et al. (114) designed a Markov decision analytic model and
performed multiple analyses. In the base-case analysis which
included older individuals with an average annual stroke risk
of 6% and falls risk of 33%, warfarin was associated with the
highest quality-adjusted life expectancy compared to aspirin or
no treatment at all. Warfarin remained the superior choice,
regardless of the annual risk (from 0 to 100%) of having a fall.
The study also estimated that an older patient taking warfarin
would need to fall 295 times a year to offset the benefits of OAC.
This suggests that the perceived falls-related ICH risk is higher
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TABLE 5 | Summary of key characteristics of the two frailty models.
Features Frailty phenotype by Fried et al. Frailty Index by Rockwood et al.
Definition Described by physical and functional characteristics An accumulation of deficits related to activities of daily living
Criteria Pre-defined/set criteria (of 5 phenotypic components) Non-fixed set of variables (of at least ≥30)
Criteria assessed • Unintentional weight loss (of more than 10 lbs in the past
year)
• Self-reported exhaustion
• Weakness (assessed by grip strength)
• Slow walking speed
• Low physical activity
Can be developed based on any symptom, sign, abnormal
laboratory value, disease classification, or disability that:
• Is present in at least 1% of the population
• Covers several organ systems
• Has no more than 5% missing data
Variables Categorical Continuous or Categorical
Frailty concept Frailty is present/absent Frailty is gradable
Frailty grading 0-Robust
1-2–Pre-frail
3-Frail
Continuous: Number between 0 and 1, where the greater the
number, the more frail a person is
Categorical:*
≤0.03–Relatively fit
>0.031–≤0.10–Less fit
>0.10–≤0.21–Least fit
>0.21–≤0.45–Frail
≥0.45–Most frail
Comprehensive
geriatric assessment
Not required Required
Cognition Does not consider cognitive impairment Considers cognitive impairment
Co-morbidities Does not consider co-morbidities Considers co-morbidities such as dementia
Prognostication Predictive of adverse outcomes Predictive of adverse outcomes
Relationship to
disability
Disability is seen as a result of frailty. No clear distinction between disability and frailty. Disabilities
contribute to frailty.
Applicability Not applicable to patients with disabilities
More suitable for immediate identification of frail/ at
risk individuals
Applicable to patients with disabilities
Can be used in the long-term follow-up of an individual
Limitations Does not include psychosocial components of frailty
Cannot be used on patients with mental/physical limitations
Certain components (e.g., grip strength) are not routinely
done in clinical practice
Time consuming to calculate
Comparison of results between different institutions may not
be possible if different variables are measured/ assessed
*Cut-off points proposed in study by Song et al. (98).
than the actual risk, owing to an increased, perhaps exaggerated
fear surrounding OAC prescriptions in older individuals. The
authors proposed that this may be due to the significance of
the event which clinicians are more likely to remember, despite
the rarity.
Despite a risk of falls, patients can continue to derive benefits
from being anticoagulated, the key one being prevention of
stroke. Thus, falls or risk of it alone should not be absolute
contraindications to OAC (114). In an observational study
of hospitalized frail, older patients, those who were non-
anticoagulated had significantly more events of ischaemic stroke
and clinically relevant bleeding after 1 year follow up, compared
to patients who were on OAC. However, no statistical difference
was observed in the rates of re-hospitalization, mortality and
falls between the anticoagulated, and non-anticoagulated groups
(110). The increased bleeding events in the non-anticoagulated
groupmay have been a reflection of their higher baseline bleeding
risk that may have led to an aversion from anticoagulation in the
first place.
In contrast, Papakonstantinou et al. (115) demonstrated
a higher all-cause mortality in non-anticoagulated old, frail
patients after 1 year of follow up. Patients discharged without
OAC had higher HEMORR2HAGES (Hepatic or renal disease,
Ethanol abuse, Malignancy, Older age, Reduced platelet count
or function, Re-bleeding, Hypertension, Anemia, Genetic factors,
Excessive fall risk, and Stroke), and clinical frailty scale (CFS)
scores and a lower Katz score indicative of an increased bleeding
risk, greater degree of frailty, and poorer functional status,
respectively. However, the study was small, and although these
findings were observed in the group without anticoagulation, it
was not clear whether these were the reasons that prevented OAC
prescription and if the increased mortality was attributable to
AF alone.
Studies looking into OAC prescription rates in frail people
have been variable. While practices in countries such as Australia
and Mexico have shown that frailty status predicted OAC use in
older adults (109, 116) there is also evidence to suggest a lack of
association between the two (117, 118). This is likely a reflection
of the variations in practice and guideline recommendations
between the regions as well as the perception of frailty by those
assessing it. A sub-study from the ORBIT-AF registry (119)
revealed that patients with cognitive impairment and frailty were
both less likely to be prescribed OAC when in fact, they had a
higher predicted risk of stroke and observedmortality. Moreover,
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TABLE 6 | Key findings from studies reporting on oral anticoagulation and cognitive impairment in AF.
References Design Population Age (±SD) Main results
Friberg et al. (45) Retrospective
cohort
444,106 74–81 After propensity score matching, no difference in the
dementia risk was observed between NOACs and VKAs (HR
0.97, 95% CI 0.67–1.40)
Mongkhon et al.
(134)
Meta-analysis 452,878 71–81 OAC use reduced dementia risk compared to no OAC use
(RR 0.79, 95% CI 0.67–0.93) A higher percentage of TTR
significantly reduced dementia risk (RR 0.38, 95% CI
0.22–0.64)
Cheng et al. (133) Meta-analysis 471,057 > 63 OACs reduced cognitive impairment in patients with AF (HR
0.71, 95% CI 69–0.74; P < 0.00001)
NOACs were better than warfarin in terms of the protective
effect on cognition (HR 0.51, 95% CI 0.37–0.71; P
< 0.00001)
Moffitt et al. (136) Meta-analysis 18,876 – No definitive evidence of cognitive benefit or harm from
anticoagulation
Mavaddat (135) RCT 973 81.5 ± 4.3 No evidence that anticoagulation protects against cognitive
decline
Madhavan et al.
(119)
Observational 2,800 71.2 OAC with warfarin was associated with an ∼22% lower risk
of dementia (HR 0.78, 95% CI 0.64–0.97)
Jacobs et al. (137) Retrospective
cohort
5,254 72.4 ± 10.9 Compared to warfarin, patients on NOACs were 43% less
likely to develop stroke/TIA/dementia (HR 0.57, 95% CI
0.17–1.97; p = 0.38)
Bunch et al. (138) Retrospective
cohort
10,537 69.3 ± 10.9 Low TTR increased risk of dementia in AF (HR = 2.51, P =
0.005)
Barber et al. (139) Observational 258 72 Warfarin use compared to aspirin, was associated with
reduced prevalence of dementia (18 vs. 32% P = 0.023)
OAC, oral anticoagulants; HR, hazard ratio; NOACSs, novel anticoagulants; TIA, transient ischaemic attack; TTR, time therapeutic range; AF, atrial fibrillation; RCT, Randomized Controlled
Trial, RR, risk ratio; CI, confidence interval; VKA, vitamin-K antagonist.
the multivariable analysis demonstrated that there were no
interactions between OAC use and frailty, in their associations
with mortality, major bleeding, and the composite end point
of stroke, systemic embolism, TIA, myocardial infarction, and
cardiovascular death.
Nevertheless, the OAC prescription rate of 70% observed
in the FRAIL-AF study (120) compared to rates of 35–65%
seen in historical studies was encouraging, as it suggested
a more judicious use of OAC in older patients, particularly
as a significant proportion in the study had diagnoses
such as dementia. However, the authors noted that non-
frail to moderately frail patients were 3.5 times more likely
to receive OAC than severely frail patients, irrespective of
their thromboembolic and bleeding risk, highlighting that
the impression of severe frailty significantly influenced OAC
prescription decisions. This emphasizes an important point,
which is the absence of a standard for assessing frailty and its
severity, even with the availability of a vast number of frailty
assessment tools, as alluded to before. Adjudication of the degree
of frailty is thereby left at the physicians’ discretion, often
influenced by their own knowledge and experience or a lack
thereof. For many, the perception of frailty is accompanied by a
sentiment of futility towards prescribing OAC; another key issue
that underlies OAC under-prescription and its consequences.
The rising prevalence of frailty necessitates the establishment
of a simple and robust frailty assessment tool, applicable to
all patients and clinicians. More and more patients with AF
are seen outside cardiac settings and similarly, the majority of
patients seen in cardiovascular settings comprise older, possibly
frail individuals. Hence, the relevance of frailty assessments
is no longer limited to geriatricians (or cardiologists) and a
validated frailty assessment tool that can be easily utilized for
risk stratification is needed to guide decision-making regarding
OAC (94). Indeed, presence of frailty should not be the sole
determinant and for this reason, having a pre-set cut-off beyond
which OAC would not be prescribed may be unwise, as it may
lead to an unjustified preclusion of treatment and act as a barrier
to an individualized treatment approach. Denying OAC in a frail
patient may achieve nothing but a debilitating stroke that adds to
their frailty and burden.
ESC guidelines for AF management include a brief section
on frail and “elderly” patients which discusses limited available
evidence but no recommendations are made with regards to
OAC therapy (34). Addressing this with consensus guidelines will
undoubtedly benefit patients and physicians.
COGNITIVE IMPAIRMENT
Several studies have shown an increased incidence of cognitive
decline and dementia, including Alzheimer’s and vascular
dementia, in patients with AF (121–123). Dementia and AF
share common cardiovascular risk factors such as heart failure,
hypertension, excessive alcohol intake, smoking and diabetes
mellitus that could account for this link (124). Regardless,
longitudinal studies adjusted for these comorbidities have still
shown an association between AF and cognitive impairment
(121, 125).
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A number of mechanisms have been proposed, and the most
familiar concept is the thromboembolic phenomenon which
clinically presents as a stroke, resulting in cerebral infarction.
However, cognitive decline has been observed even in the absence
of strokes and small vessel disease and/or cerebral microinfarcts
have been identified as an underlying cause (126). These
“silent” strokes have no clinical manifestation, only apparent on
neuroimaging. AF is considered an independent risk factor for
cerebral microinfarcts (127).
Another proposed explanation for the link between AF and
cognitive impairment is the beat-to-beat variability that occurs
in AF, leading to intermittent cerebral hypoperfusion. This in
turn results in cerebral ischaemia, particularly in the white-
matter regions, and is regarded as a frequent mechanism for
cognitive impairment in AF (128, 129). Other inflammatory and
neurohormonal processes are also likely contributory (127).
The meta-analysis by Kalantarian et al. (130) highlighted a
significant association between AF and dementia, independent
of stroke. In the Atherosclerosis Risk in Communities
Neurocognitive (ARIC-NCS) study (131) which followed
12,515 patients for over 20 years, incident AF was associated with
a 23% higher risk of dementia, even after adjustments were made
for cardio- and cerebrovascular risk factors as well as prevalent
and incident ischaemic stroke. The mean age of the participants
was 56.9 ± 5.7 and although the incidence rates of dementia
were significant in those under and over the age of 57 years, it
was more pronounced in the >57 years group. In contrast, the
Rotterdam study (132) which also prospectively followed 6,514
individuals for a similar length of time showed that the risk of
dementia was confined only to the younger participants with
incident AF, who were <67 years. Further, there appeared to be
a dose-response relationship as those who had AF for a longer
duration were more likely to develop dementia. This is plausible
as dementia develops over many years and AF needs to develop
at a younger age to contribute to the onset of this condition at a
later stage.
The association between AF and dementia has fuelled a
vast amount of research to determine if OACs have any
therapeutic benefit in attenuating this risk. Given that OACs
largely address the thromboembolic complications when taken
appropriately, this should theoretically be the case, though
cognitive impairment arising from hypoperfusion and related
mechanisms would remain unaffected (127). Existing evidence
relating to this subject is non-conclusive with some studies
demonstrating a reduction in the incidence of dementia with
OACs (133, 134) and others suggesting otherwise (135, 136)
(Table 6). The studies where no improvements were observed
with OAC were mainly warfarin-based and the quality of anti-
coagulation control, that is less likely to be achieved with VKAs
such as warfarin may explain this observation. Cheng et al. (133)
in a meta-analysis recognized that TTR appeared to play an
important role in cognitive benefit as TTR <25% significantly
increased risk of dementia compared to TTR ≥ 75% (HR 3.02,
95% CI 1.12–8.91; P = 0.03). Non-adherence, polypharmacy,
comorbidities, and drug interactions can all have an impact on
TTR in older people but are less likely to influence the quality of
anticoagulation with NOACs.
Recent evidence suggests that NOACs may be preferable
for reducing incidence of dementia (137). They may also
improve adherence as they can be given as once or twice daily
regimens without the need for frequent follow-up and can easily
be incorporated into multi-drug regimens as well as blister
packs and dosette boxes, in patients with cognitive impairment.
However, opinions are mixed on whether NOACs or VKAs are
better for adherence, in the context of cognitive impairment
(140, 141). Persistence with therapy is also a challenge, and efforts
to improve persistence and adherence are needed (142, 143).
On balance OACs, particularly NOACs, appear to be
beneficial for reducing the risk of dementia, owing to the
reduction in silent cerebral ischaemia or microemboli. However,
well-designed RCTs adjusting for confounders, with a longer
duration of follow up are awaited to fully explore the impact of
OAC on cognitive function (144).
Despite the established benefits of OAC, cognitive impairment
remains another reported reason precluding OAC use, over fears
of a drug overdose or falls which can result in a bleed. Most
individuals with cognitive impairment have their medications
administered and are under substantial supervision either by
their family members at home or carers in long-term care
facilities. In such cases, the likelihood of overdosing on an OAC
or incurring harm due to an environmental hazard is low and
withholding OAC would only increase the chances of developing
a stroke which can cause a greater disability. Of course, there
are always more complex cases and in such situations, it may be
prudent to have multi-discliplinary discussions to determine the
best course of action.
The risk of falls and dementia are addressed in current ESC
guidelines which advise withholding OAC only in patients who
are likely to have severe uncontrollable falls (e.g., epilepsy) or in
selected patients with dementia where caregivers cannot ensure
compliance and treatment adherence (34).
RATE vs. RHYTHM CONTROL IN OLDER
PEOPLE
Current NICE guidelines in the UK, recommend that clinicians
consider rate control as first line except in the following cases: AF
has a reversible cause, new-onset AF, heart failure caused by AF,
patients with atrial flutter suitable for ablation and cases where
rhythm control is more suitable based on clinical judgement (35).
The ESC in their guidance suggests that rhythm control may be
indicated in patients who remain symptomatic despite adequate
rate control therapy. ESC maintains that the evidence for both
rhythm control and rate control is fairly balanced but recognize
that data regarding modern rhythm control strategies such as
catheter ablation, combination therapy, and early treatment is
awaited (34). American guidelines are also on par and outline
situations where rhythm control strategies may be attempted and
this includes a younger, rather than older patient age (36).
Given that AF is an abnormality of cardiac rhythm, it is
reasonable to assume that rhythm control is favorable over
rate control. However, in a sub-analysis of the AFFIRM
(Atrial Fibrillation Follow-up Investigation of Rhythm
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Management) Trial (145) all-cause mortality was significantly
lower in the rate controlled group who were between 70
and 80 years old, compared to the respective rhythm control
group (HR 0.77, 95% CI0.63–0.94, p = 0.01). All-cause
hospitalization was also lower in this group (HR 0.76,
95% CI 0.68–0.86; P < 0.001). There were no differences
in the incidence of stroke or major bleeding between the
two arms.
An ancillary analysis of the REPOSI study (146), a multi-
center observational registry, did not demonstrate significant
differences in the cardiovascular and all-cause mortality of older
patients managed using rate and rhythm control strategies. In the
study, the rate control group was older and had higher rates of
polypharmacy, heart failure, and diabetes. Conversely, patients
on rhythm control were younger with fewer comorbidities and
a better cognitive status. 83% of patients in the study were
managed using rate control strategies, indicating that this is the
preferred method. This could be because they are viewed as
more conservative and less burdensome on older people, and
particularly as it makes no difference to the OAC status as
its continuation is still recommended due to the high risk of
AF recurrence.
Rate control vs. rhythm control strategies for AF continue
to be debated in the literature; however there is paucity of data
with respect to those who are of an older age. Whilst some
studies suggest that rate control strategies are superior in terms of
cost-effectiveness (147), others have noted better outcomes and
health-related quality of life with rhythm control interventions
(148, 149). Nonetheless, real world studies indicate that rate
control is more favored and the vast majority of older patients
are managed this way (41).
CONCLUSION
AF is a significant global health burden that is more
prevalent in older people. Management of this condition in
the geriatric population is riddled with clinical dilemmas. They
are accompanied by a high thromboembolic risk but also a
concomitant high bleeding risk, requiring clinicians to balance
the NCB (150). Indeed, these require deliberation to prevent
harm to patients but often, clinical situations are complicated
by the under-estimation of the thromboembolic risk and over-
estimation of the bleeding risk. Consequently, OACs continue to
be under-used in older individuals.
When making decisions regarding OAC, chronological age is
of less importance and biological age, indicated by an individual’s
frailty and functional status as well as factors such as cognitive
impairment must be given careful attention. Nevertheless, their
presence should not be regarded as absolute contraindications
to OAC use. Risk factor modification, identification of barriers
to treatment and involvement of patients and their family
members are crucial to the initiation of OAC and improvement of
treatment adherence. In the absence of contraindications and as
allowed by patients’ risk factor profiles, clinicians should explore
NOACs as an alternative to conventional VKAs, particularly as
they have been shown to reduce the risk of ICH.
OAC prescription practice in older individuals largely
varies between regions and even from physician to physician
within the same locality. While some guidelines are starting to
address certain difficulties faced in treating old patients with
OAC, further improvements are needed including consensus
recommendations, although the challenges to this must
be appreciated.
With the aging population and the anticipated rise in AF
prevalence, it is imperative that regulatory bodies and clinicians
take responsibility to ensure patients with this condition
are treated appropriately and holistically. Indeed, there is a
move toward a more integrated or holistic approach to AF
management that can be summed up as follows: “A” Avoid
stroke; “B” Better symptom control with symptom directed
decisions on rate or rhythm control; “C” Cardiovascular
risk, and comorbidity management, including attention to
lifestyle changes (151). Such an integrated approach has been
associated with improved outcomes and reduced healthcare
costs (152–154).
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